🇺🇸 NVP in United States
24 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 24
Most-reported reactions
- Neuropathy Peripheral — 4 reports (16.67%)
- Fanconi Syndrome Acquired — 3 reports (12.5%)
- Nephropathy Toxic — 3 reports (12.5%)
- Acute Kidney Injury — 2 reports (8.33%)
- Anaemia — 2 reports (8.33%)
- Confusional State — 2 reports (8.33%)
- Drug Ineffective — 2 reports (8.33%)
- Duodenitis — 2 reports (8.33%)
- Gastritis — 2 reports (8.33%)
- Proteinuria — 2 reports (8.33%)
NVP in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is NVP approved in United States?
NVP does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for NVP in United States?
Johns Hopkins Bloomberg School of Public Health is the originator. The local marketing authorisation holder may differ — check the official source linked above.